3349 COSMOS Pharmaceutical Corporation - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3349

TSE Prime

COSMOS Pharmaceutical Corporation

7,463

JPY

-34

(-0.45%)

Dec 5, 1:38 pm JST

48.15

USD

Dec 4, 11:38 pm EST

Result

PTS

outside of trading hours

7,478

Dec 5, 12:56 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
May, 2022	755,414	29,796	32,861	23,155	292.4	40	Jul 11, 2022	J-GAAP
May, 2023	827,697	30,128	33,086	23,797	300.5	50	Jul 10, 2023	J-GAAP
May, 2024	964,989	31,501	34,299	24,454	308.6	60	Jul 12, 2024	J-GAAP
May, 2025	1,011,390	40,404	43,160	30,978	390.9	70	Jul 11, 2025	J-GAAP
May, 2026 Guidance	1,057,000	40,500	43,200	31,000	391.1	75	Jul 11, 2025	J-GAAP
YoY	+4.5%	+0.2%	+0.1%	+0.1%	+0.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
May, 2021	Jul 10, 2020	723,000	29,100	31,600	21,780	27.5*	J-GAAP
Results	Jul 12, 2021	726,424	33,147	35,835	27,156	35*	J-GAAP
May, 2022	Jul 12, 2021	Available in future release
Results	Jul 11, 2022
May, 2023	Jul 11, 2022
Results	Jul 10, 2023
May, 2024	Jul 10, 2023
Results	Jul 12, 2024
May, 2025	Jul 12, 2024
Results	Jul 11, 2025
May, 2026	Jul 11, 2025	1,057,000	40,500	43,200	31,000	75	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
May, 2001	12,396	－	Available in future release
May, 2002	22,524	+81.7
May, 2003	42,413	+88.3
May, 2004	59,413	+40.1
May, 2005	78,651	+32.4
May, 2006	105,046	+33.6
May, 2007	125,846	+19.8
May, 2008	148,244	+17.8
May, 2009	177,756	+19.9
May, 2010	205,387	+15.5
May, 2011	237,174	+15.5
May, 2012	279,021	+17.6
May, 2013	329,313	+18.0
May, 2014	371,825	+12.9
May, 2015	408,466	+9.9
May, 2016	447,273	+9.5
May, 2017	502,732	+12.4
May, 2018	557,999	+11.0
May, 2019	611,137	+9.5
May, 2020	684,403	+12.0
May, 2021	726,424	+6.1
May, 2022	755,414	+4.0
May, 2023	827,697	+9.6
May, 2024	964,989	+16.6
May, 2025	1,011,390	+4.8
May, 2026 Guidance	1,057,000	+4.5	40,500	+0.2	43,200	+0.1	391.1	+0.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
May, 2024	964,989	31,501	3.26	11.05	5.45	2.15	308.6
May, 2025	1,011,390	40,404	3.99	12.67	6.19	2.02	390.9
May, 2026 Guidance	1,057,000	40,500	3.83	11.80	5.91	2.02	391.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,011,390	40,404	43,160	30,978	390.9
Fiscal Year	May, 2025	May, 2025	May, 2025	May, 2025	May, 2025

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jun - Nov, 2022	404,016	15,385	16,900	11,299	142.7	21.25	Jan 13, 2023	J-GAAP
Jun - Nov, 2023	476,430	15,836	17,346	11,587	146.3	30	Jan 12, 2024	J-GAAP
Jun - Nov, 2024	505,936	20,344	21,777	14,428	182.1	32.50	Jan 10, 2025	J-GAAP
Jun - Nov, 2025 Guidance	525,000	20,420	21,780	14,650	184.8	37.50	Jul 11, 2025	J-GAAP
YoY	+3.8%	+0.4%	+0.0%	+1.5%	+1.5%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Nov, 2022	Jul 11, 2022	400,000	14,920	16,420	11,100	21.25	J-GAAP
Results	Jan 13, 2023	404,016	15,385	16,900	11,299	21.25	J-GAAP
Nov, 2023	Jul 10, 2023	Available in future release
Results	Jan 12, 2024
Nov, 2024	Jul 12, 2024
Results	Jan 10, 2025
Nov, 2025	Jul 11, 2025	525,000	20,420	21,780	14,650	37.5	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
May, 2023	30,128	5,321	54,434	-49,113	3,245	45,928	10.91	J-GAAP
May, 2024	31,501	-2,154	55,175	-57,329	8,527	52,301	10.98	J-GAAP
May, 2025	40,404	-2,981	52,467	-55,448	7,717	57,038	10.87	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jun - Aug, 2023	241,653	8,990	9,699	6,508	82.2	55.9	Oct 11, 2023	J-GAAP
Jun - Aug, 2024	261,841	11,580	12,293	8,143	102.7	56.4	Oct 11, 2024	J-GAAP
Jun - Aug, 2025	272,394	11,645	12,188	8,171	103.1	56.0	Oct 14, 2025	J-GAAP
YoY	+4.0%	+0.6%	-0.9%	+0.3%	+0.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Sep - Nov, 2023	234,777	6,846	7,647	5,079	64.1	2.9	Jan 12, 2024	J-GAAP
Dec - Feb, 2023	238,881	7,902	8,568	5,770	72.8	3.3	Apr 12, 2024	J-GAAP
Mar - May, 2024	249,678	7,763	8,385	7,097	89.6	3.1	Jul 12, 2024	J-GAAP
Jun - Aug, 2024	261,841	11,580	12,293	8,143	102.7	4.4	Oct 11, 2024	J-GAAP
Sep - Nov, 2024	244,095	8,764	9,484	6,285	79.3	3.6	Jan 10, 2025	J-GAAP
Dec - Feb, 2024	246,332	11,283	11,994	7,915	99.9	4.6	Apr 14, 2025	J-GAAP
Mar - May, 2025	259,122	8,777	9,389	8,635	109.0	3.4	Jul 11, 2025	J-GAAP
Jun - Aug, 2025	272,394	11,645	12,188	8,171	103.1	4.3	Oct 14, 2025	J-GAAP
YoY	+4.0%	+0.6%	-0.9%	+0.3%	+0.4%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep - Nov, 2020	175,014	+8.9	Available in future release
Dec - Feb, 2020	177,522	+5.9
Mar - May, 2021	184,727	-3.5
Jun - Aug, 2021	189,409	+0.1
Sep - Nov, 2021	181,729	+3.8
Dec - Feb, 2021	187,747	+5.8
Mar - May, 2022	196,529	+6.4
Jun - Aug, 2022	206,122	+8.8
Sep - Nov, 2022	197,894	+8.9
Dec - Feb, 2022	202,286	+7.7
Mar - May, 2023	221,395	+12.7
Jun - Aug, 2023	241,653	+17.2
Sep - Nov, 2023	234,777	+18.6
Dec - Feb, 2023	238,881	+18.1
Mar - May, 2024	249,678	+12.8
Jun - Aug, 2024	261,841	+8.4
Sep - Nov, 2024	244,095	+4.0
Dec - Feb, 2024	246,332	+3.1
Mar - May, 2025	259,122	+3.8
Jun - Aug, 2025	272,394	+4.0	11,645	+0.6	12,188	-0.9	103.1	+0.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	272,394	11,645	12,293	8,635	109.0
Fiscal Year	Aug, 2025	Aug, 2025	Aug, 2024	May, 2025	May, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
May, 2023	5,330.26	50.1	420,967	211,072	202,485	0.09	Jul 10, 2023	J-GAAP
May, 2024	5,840.26	48.6	476,546	231,442	222,284	0.15	Jul 12, 2024	J-GAAP
May, 2025	3,248.45	49.1	524,755	257,463	248,309	0.17	Jul 11, 2025	J-GAAP
Jun - Aug, 2025	ー	50.1	524,305	262,658	253,508	0.16	Oct 14, 2025	J-GAAP

COSMOS Pharmaceutical Corporation(3349) Financial Results